Effects of benfotiamine and coenzyme Q10 on kidney damage induced gentamicin

Mehmet Alperen Ustuner1, Dilara Kaman1, Neriman Colakoglu2

  • 1Department of Medical Biochemistry, Firat University School of Medicine, Elazığ, Turkey.

Tissue & Cell
|October 26, 2017
PubMed
Abstract

Insights

Benfotiamine (BFT) protects against gentamicin-induced kidney damage by reducing oxidative stress and inflammation. Coenzyme Q10 (CoQ10) showed some protective effects but were less significant than BFT.

Area of Science:

  • Nephrology
  • Pharmacology
  • Toxicology

Background:

  • Gentamicin (GM) is a vital antibiotic for severe infections.
  • GM use is limited by its nephrotoxicity.
  • Investigating protective agents against GM-induced kidney damage is crucial.

Purpose of the Study:

  • To evaluate the protective effects of benfotiamine (BFT) and coenzyme Q10 (CoQ10) against gentamicin-induced nephrotoxicity in rats.
  • To assess the impact of BFT and CoQ10 on oxidative stress and inflammation markers in GM-treated rats.

Main Methods:

  • Rats were administered gentamicin (GM) alone or in combination with BFT or CoQ10 for 8 days.
  • Serum markers of kidney function (urea, creatinine, KIM-1) were measured.
  • Oxidant/antioxidant parameters and histopathological changes in renal tissues were analyzed.

Main Results:

  • GM induced significant nephrotoxicity, marked by elevated creatinine, urea, KIM-1, malondialdehyde, and reduced glutathione.
  • GM treatment led to severe tubular necrosis and hyaline cast accumulation.
  • BFT administration notably normalized kidney function markers and reduced histological damage.
  • CoQ10 showed a trend towards reducing tubular damage but did not significantly alter measured biochemical parameters compared to GM alone.

Conclusions:

  • Benfotiamine (BFT) effectively attenuates gentamicin-induced nephrotoxicity.
  • BFT ameliorates renal injury by mitigating oxidative stress and inflammation.
  • CoQ10 offers some protective effects, but BFT demonstrates superior renoprotective capabilities in this model.

Related Concept Videos

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
280
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
506
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
282
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
359
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
851
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
265